BioMedica touts mid-stage Trovax trial data

The UK's Oxford BioMedica touted preliminary mid-stage results for its cancer drug Trovax, saying that the drug demonstrated a strong anti-tumor immune response and was safe and well tolerated among patients with renal cell carcinoma. So far seven patients have been enrolled in the study and results are available for five. A total of 25 patients are being enrolled to complete the trial.

- read this press release for more